Hypoglycemia in a patient with pleural solitary fibrous tumor and response to pasireotide
Introduction: hypoglycemia is a common and multifactorial clinical condition. A rare cause is that associated with non-islet cell tumors. Objective: to report our experience on the management of severe hypoglycemia in a patient with solitary pleural fibrous tumor and his response to pasireotide. Cli...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Artículo revista |
| Lenguaje: | Español |
| Publicado: |
Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología
2025
|
| Materias: | |
| Acceso en línea: | https://revistas.unc.edu.ar/index.php/med/article/view/44424 |
| Aporte de: |
| id |
I10-R327-article-44424 |
|---|---|
| record_format |
ojs |
| institution |
Universidad Nacional de Córdoba |
| institution_str |
I-10 |
| repository_str |
R-327 |
| container_title_str |
Revista de la Facultad de Ciencias Médicas de Córdoba |
| language |
Español |
| format |
Artículo revista |
| topic |
hypoglycemia pleural cavity neoplasm hipoglucemia pleura neoplasia glicemia cavidade pleural neoplasias |
| spellingShingle |
hypoglycemia pleural cavity neoplasm hipoglucemia pleura neoplasia glicemia cavidade pleural neoplasias Videla, Elizabeth Karen Ferrada, Pablo Miller, Jorge Torres, Eduardo Álvarez, Analía Herrera, Javier de la Torre, Bertha Videla, Elizabeth Karen Ferrada, Pablo Miller, Jorge Torres , Eduardo Álvarez, Analía Herrera, Javier de la Torre, Bertha Videla, Elizabeth Karen Ferrada, Pablo Miller, Jorge Torres, Eduardo Álvarez, Analía Herrera, Javier de la Torre, Bertha Hypoglycemia in a patient with pleural solitary fibrous tumor and response to pasireotide |
| topic_facet |
hypoglycemia pleural cavity neoplasm hipoglucemia pleura neoplasia glicemia cavidade pleural neoplasias |
| author |
Videla, Elizabeth Karen Ferrada, Pablo Miller, Jorge Torres, Eduardo Álvarez, Analía Herrera, Javier de la Torre, Bertha Videla, Elizabeth Karen Ferrada, Pablo Miller, Jorge Torres , Eduardo Álvarez, Analía Herrera, Javier de la Torre, Bertha Videla, Elizabeth Karen Ferrada, Pablo Miller, Jorge Torres, Eduardo Álvarez, Analía Herrera, Javier de la Torre, Bertha |
| author_facet |
Videla, Elizabeth Karen Ferrada, Pablo Miller, Jorge Torres, Eduardo Álvarez, Analía Herrera, Javier de la Torre, Bertha Videla, Elizabeth Karen Ferrada, Pablo Miller, Jorge Torres , Eduardo Álvarez, Analía Herrera, Javier de la Torre, Bertha Videla, Elizabeth Karen Ferrada, Pablo Miller, Jorge Torres, Eduardo Álvarez, Analía Herrera, Javier de la Torre, Bertha |
| author_sort |
Videla, Elizabeth Karen |
| title |
Hypoglycemia in a patient with pleural solitary fibrous tumor and response to pasireotide |
| title_short |
Hypoglycemia in a patient with pleural solitary fibrous tumor and response to pasireotide |
| title_full |
Hypoglycemia in a patient with pleural solitary fibrous tumor and response to pasireotide |
| title_fullStr |
Hypoglycemia in a patient with pleural solitary fibrous tumor and response to pasireotide |
| title_full_unstemmed |
Hypoglycemia in a patient with pleural solitary fibrous tumor and response to pasireotide |
| title_sort |
hypoglycemia in a patient with pleural solitary fibrous tumor and response to pasireotide |
| description |
Introduction: hypoglycemia is a common and multifactorial clinical condition. A rare cause is that associated with non-islet cell tumors.
Objective: to report our experience on the management of severe hypoglycemia in a patient with solitary pleural fibrous tumor and his response to pasireotide.
Clinical case: 63-year-old patient with a history of glomerulonephritis, hypothyroidism, arterial hypertension and a one-year diagnosis of solitary pleural fibrous tumor. Referred to endocrinology due to hypoglycemia for 6 months. Acromegaloid features were confirmed. Laboratory: Hct 36%, Hb 11.9 g/dl, GB 3570/mm3 (Eo 2%, Ba2%, Bac 4%, NS 36%, Li 30%, Mo 14% metamyelocytes 1%, myelocytes 11%), platelets 120,000 /mm3, ESR 10 mm, CRP 9 mg/L, TP 114%, TTPK 25 sec, blood glucose 57 mg/dL, renal function, hepatogram and lipid profile without particularities. IGF-1 84 ng/ml (VR 57 - 188), C-peptide 0.10 ng/ml (VR 1.10 - 4.40), somatotropin 0.98 ng/ml (VR up to 2.5) and basal insulin 0.4 uU/ml (VR 2.6 - 24) . IFG-2 measurement is not available in Argentina. A chest CT showed a pleural tumor measuring 13 cm. Without possibilities of surgical resection and without response to chemotherapy. Treatment was started with infusion of 25% dextrose, dexamethasone, pasireotide with good response. The patient died due to an infectious complication.
Conclusion: pasireotide could be a therapeutic alternative in cases that are not candidates for surgery or refractory to other medical treatment. |
| publisher |
Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología |
| publishDate |
2025 |
| url |
https://revistas.unc.edu.ar/index.php/med/article/view/44424 |
| work_keys_str_mv |
AT videlaelizabethkaren hypoglycemiainapatientwithpleuralsolitaryfibroustumorandresponsetopasireotide AT ferradapablo hypoglycemiainapatientwithpleuralsolitaryfibroustumorandresponsetopasireotide AT millerjorge hypoglycemiainapatientwithpleuralsolitaryfibroustumorandresponsetopasireotide AT torreseduardo hypoglycemiainapatientwithpleuralsolitaryfibroustumorandresponsetopasireotide AT alvarezanalia hypoglycemiainapatientwithpleuralsolitaryfibroustumorandresponsetopasireotide AT herrerajavier hypoglycemiainapatientwithpleuralsolitaryfibroustumorandresponsetopasireotide AT delatorrebertha hypoglycemiainapatientwithpleuralsolitaryfibroustumorandresponsetopasireotide AT videlaelizabethkaren hypoglycemiainapatientwithpleuralsolitaryfibroustumorandresponsetopasireotide AT ferradapablo hypoglycemiainapatientwithpleuralsolitaryfibroustumorandresponsetopasireotide AT millerjorge hypoglycemiainapatientwithpleuralsolitaryfibroustumorandresponsetopasireotide AT torreseduardo hypoglycemiainapatientwithpleuralsolitaryfibroustumorandresponsetopasireotide AT alvarezanalia hypoglycemiainapatientwithpleuralsolitaryfibroustumorandresponsetopasireotide AT herrerajavier hypoglycemiainapatientwithpleuralsolitaryfibroustumorandresponsetopasireotide AT delatorrebertha hypoglycemiainapatientwithpleuralsolitaryfibroustumorandresponsetopasireotide AT videlaelizabethkaren hypoglycemiainapatientwithpleuralsolitaryfibroustumorandresponsetopasireotide AT ferradapablo hypoglycemiainapatientwithpleuralsolitaryfibroustumorandresponsetopasireotide AT millerjorge hypoglycemiainapatientwithpleuralsolitaryfibroustumorandresponsetopasireotide AT torreseduardo hypoglycemiainapatientwithpleuralsolitaryfibroustumorandresponsetopasireotide AT alvarezanalia hypoglycemiainapatientwithpleuralsolitaryfibroustumorandresponsetopasireotide AT herrerajavier hypoglycemiainapatientwithpleuralsolitaryfibroustumorandresponsetopasireotide AT delatorrebertha hypoglycemiainapatientwithpleuralsolitaryfibroustumorandresponsetopasireotide AT videlaelizabethkaren hipoglucemiaenunpacientecontumorfibrososolitariopleuralyrespuestaapasireotide AT ferradapablo hipoglucemiaenunpacientecontumorfibrososolitariopleuralyrespuestaapasireotide AT millerjorge hipoglucemiaenunpacientecontumorfibrososolitariopleuralyrespuestaapasireotide AT torreseduardo hipoglucemiaenunpacientecontumorfibrososolitariopleuralyrespuestaapasireotide AT alvarezanalia hipoglucemiaenunpacientecontumorfibrososolitariopleuralyrespuestaapasireotide AT herrerajavier hipoglucemiaenunpacientecontumorfibrososolitariopleuralyrespuestaapasireotide AT delatorrebertha hipoglucemiaenunpacientecontumorfibrososolitariopleuralyrespuestaapasireotide AT videlaelizabethkaren hipoglucemiaenunpacientecontumorfibrososolitariopleuralyrespuestaapasireotide AT ferradapablo hipoglucemiaenunpacientecontumorfibrososolitariopleuralyrespuestaapasireotide AT millerjorge hipoglucemiaenunpacientecontumorfibrososolitariopleuralyrespuestaapasireotide AT torreseduardo hipoglucemiaenunpacientecontumorfibrososolitariopleuralyrespuestaapasireotide AT alvarezanalia hipoglucemiaenunpacientecontumorfibrososolitariopleuralyrespuestaapasireotide AT herrerajavier hipoglucemiaenunpacientecontumorfibrososolitariopleuralyrespuestaapasireotide AT delatorrebertha hipoglucemiaenunpacientecontumorfibrososolitariopleuralyrespuestaapasireotide AT videlaelizabethkaren hipoglucemiaenunpacientecontumorfibrososolitariopleuralyrespuestaapasireotide AT ferradapablo hipoglucemiaenunpacientecontumorfibrososolitariopleuralyrespuestaapasireotide AT millerjorge hipoglucemiaenunpacientecontumorfibrososolitariopleuralyrespuestaapasireotide AT torreseduardo hipoglucemiaenunpacientecontumorfibrososolitariopleuralyrespuestaapasireotide AT alvarezanalia hipoglucemiaenunpacientecontumorfibrososolitariopleuralyrespuestaapasireotide AT herrerajavier hipoglucemiaenunpacientecontumorfibrososolitariopleuralyrespuestaapasireotide AT delatorrebertha hipoglucemiaenunpacientecontumorfibrososolitariopleuralyrespuestaapasireotide AT videlaelizabethkaren hipoglicemiaempacientecomtumorfibrososolitariopleuralerespostaaopasireotida AT ferradapablo hipoglicemiaempacientecomtumorfibrososolitariopleuralerespostaaopasireotida AT millerjorge hipoglicemiaempacientecomtumorfibrososolitariopleuralerespostaaopasireotida AT torreseduardo hipoglicemiaempacientecomtumorfibrososolitariopleuralerespostaaopasireotida AT alvarezanalia hipoglicemiaempacientecomtumorfibrososolitariopleuralerespostaaopasireotida AT herrerajavier hipoglicemiaempacientecomtumorfibrososolitariopleuralerespostaaopasireotida AT delatorrebertha hipoglicemiaempacientecomtumorfibrososolitariopleuralerespostaaopasireotida AT videlaelizabethkaren hipoglicemiaempacientecomtumorfibrososolitariopleuralerespostaaopasireotida AT ferradapablo hipoglicemiaempacientecomtumorfibrososolitariopleuralerespostaaopasireotida AT millerjorge hipoglicemiaempacientecomtumorfibrososolitariopleuralerespostaaopasireotida AT torreseduardo hipoglicemiaempacientecomtumorfibrososolitariopleuralerespostaaopasireotida AT alvarezanalia hipoglicemiaempacientecomtumorfibrososolitariopleuralerespostaaopasireotida AT herrerajavier hipoglicemiaempacientecomtumorfibrososolitariopleuralerespostaaopasireotida AT delatorrebertha hipoglicemiaempacientecomtumorfibrososolitariopleuralerespostaaopasireotida AT videlaelizabethkaren hipoglicemiaempacientecomtumorfibrososolitariopleuralerespostaaopasireotida AT ferradapablo hipoglicemiaempacientecomtumorfibrososolitariopleuralerespostaaopasireotida AT millerjorge hipoglicemiaempacientecomtumorfibrososolitariopleuralerespostaaopasireotida AT torreseduardo hipoglicemiaempacientecomtumorfibrososolitariopleuralerespostaaopasireotida AT alvarezanalia hipoglicemiaempacientecomtumorfibrososolitariopleuralerespostaaopasireotida AT herrerajavier hipoglicemiaempacientecomtumorfibrososolitariopleuralerespostaaopasireotida AT delatorrebertha hipoglicemiaempacientecomtumorfibrososolitariopleuralerespostaaopasireotida |
| first_indexed |
2025-05-10T05:10:24Z |
| last_indexed |
2025-05-10T05:10:24Z |
| _version_ |
1831708996135813120 |
| spelling |
I10-R327-article-444242025-04-21T14:58:27Z Hypoglycemia in a patient with pleural solitary fibrous tumor and response to pasireotide Hipoglucemia en un paciente con tumor fibroso solitario pleural y respuesta a pasireotide Hipoglicemia em paciente com tumor fibroso solitário pleural e resposta ao pasireotida Videla, Elizabeth Karen Ferrada, Pablo Miller, Jorge Torres, Eduardo Álvarez, Analía Herrera, Javier de la Torre, Bertha Videla, Elizabeth Karen Ferrada, Pablo Miller, Jorge Torres , Eduardo Álvarez, Analía Herrera, Javier de la Torre, Bertha Videla, Elizabeth Karen Ferrada, Pablo Miller, Jorge Torres, Eduardo Álvarez, Analía Herrera, Javier de la Torre, Bertha hypoglycemia pleural cavity neoplasm hipoglucemia pleura neoplasia glicemia cavidade pleural neoplasias Introduction: hypoglycemia is a common and multifactorial clinical condition. A rare cause is that associated with non-islet cell tumors. Objective: to report our experience on the management of severe hypoglycemia in a patient with solitary pleural fibrous tumor and his response to pasireotide. Clinical case: 63-year-old patient with a history of glomerulonephritis, hypothyroidism, arterial hypertension and a one-year diagnosis of solitary pleural fibrous tumor. Referred to endocrinology due to hypoglycemia for 6 months. Acromegaloid features were confirmed. Laboratory: Hct 36%, Hb 11.9 g/dl, GB 3570/mm3 (Eo 2%, Ba2%, Bac 4%, NS 36%, Li 30%, Mo 14% metamyelocytes 1%, myelocytes 11%), platelets 120,000 /mm3, ESR 10 mm, CRP 9 mg/L, TP 114%, TTPK 25 sec, blood glucose 57 mg/dL, renal function, hepatogram and lipid profile without particularities. IGF-1 84 ng/ml (VR 57 - 188), C-peptide 0.10 ng/ml (VR 1.10 - 4.40), somatotropin 0.98 ng/ml (VR up to 2.5) and basal insulin 0.4 uU/ml (VR 2.6 - 24) . IFG-2 measurement is not available in Argentina. A chest CT showed a pleural tumor measuring 13 cm. Without possibilities of surgical resection and without response to chemotherapy. Treatment was started with infusion of 25% dextrose, dexamethasone, pasireotide with good response. The patient died due to an infectious complication. Conclusion: pasireotide could be a therapeutic alternative in cases that are not candidates for surgery or refractory to other medical treatment. Introducción: la hipoglucemia es una condición clínica usual y multifactorial. Una causa poco frecuente es la asociada a tumores de célula no islote. Objetivo: comunicar nuestra experiencia sobre manejo de hipoglucemias severas en un paciente con tumor fibroso solitario pleural y su respuesta a pasireotide. Caso clínico: paciente de 63 años de edad con antecedentes de glomerulonefritis, hipotiroidismo, hipertensión arterial y diagnóstico de un año de evolución de tumor fibroso solitario pleural. Derivado a endocrinología por hipoglucemias desde hace 6 meses. Se constataron rasgos acromegaloides. Laboratorio: Hto 36%, Hb 11.9 g/dl, GB 3570/mm3 (Eo 2%, Ba2%, Bac 4%, NS 36%, Li 30%, Mo 14% metamielocitos 1%, mielocitos 11%), plaquetas 120000/mm3, VSG 10 mm, PCR 9 mg/L, TP 114%, TTPK 25 seg, glucemia 57 mg/dL, función renal, hepatograma y perfil lipídico sin particularidades. IGF-1 84 ng/ml (VR 57 - 188), péptido C 0.10 ng/ml (VR 1.10 - 4.40), somatotrofina 0.98 ng/ml (VR hasta 2.5) e insulina basal 0.4 uU/ml (VR 2.6 - 24). No se dispone de medición de IFG-2 en Argentina. En TC de tórax presentaba tumor pleural de 13 cm de extensión. Sin posibilidades de resección quirúrgica y sin respuesta a quimioterapia. Se inicia tratamiento con infusión de dextrosa 25%, dexametasona, pasireotide con buena respuesta. El paciente falleció por complicación infecciosa. Conclusión: el pasireotide podría ser una alterativa terapéutica ante casos no candidatos a cirugía o refractarios a otro tratamiento médico. Introdução: a hipoglicemia é uma condição clínica comum e multifatorial. Uma causa rara é aquela associada a tumores de células não-ilhotas. Objetivo: relatar nossa experiência no manejo da hipoglicemia grave em paciente com tumor fibroso pleural solitário e sua resposta ao pasireotida. Caso clínico: Paciente de 63 anos com história de glomerulonefrite, hipotireoidismo, hipertensão arterial e diagnóstico de tumor fibroso pleural solitário há um ano. Encaminhada à endocrinologia por hipoglicemia há 6 meses. Características acromegalóides foram confirmadas. Laboratório: Hct 36%, Hb 11,9 g/dl, GB 3570/mm3 (Eo 2%, Ba2%, Bac 4%, NS 36%, Li 30%, Mo 14% metamielócitos 1%, mielócitos 11%), plaquetas 120.000 /mm3, VHS 10 mm, PCR 9 mg/L, TP 114%, TTPK 25 seg, glicemia 57 mg/dL, função renal, hepatograma e perfil lipídico sem particularidades. IGF-1 84 ng/ml (VR 57 - 188), peptídeo C 0,10 ng/ml (VR 1,10 - 4,40), somatotropina 0,98 ng/ml (VR até 2,5) e insulina basal 0,4 uU/ml (VR 2,6 - 24). A medição do IFG-2 não está disponível na Argentina. A tomografia computadorizada de tórax mostrou tumor pleural medindo 13 cm. Sem possibilidades de ressecção cirúrgica e sem resposta à quimioterapia. O tratamento foi iniciado com infusão de dextrose 25%, dexametasona, pasireotida com boa resposta. O paciente faleceu devido a uma complicação infecciosa. Conclusão: o pasireotida pode ser uma alternativa terapêutica em casos não candidatos à cirurgia ou refratários a outro tratamento médico. Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología 2025-03-31 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion application/pdf text/html https://revistas.unc.edu.ar/index.php/med/article/view/44424 10.31053/1853.0605.v82.n1.44424 Revista de la Facultad de Ciencias Médicas de Córdoba.; Vol. 82 No. 1 (2025); 127-139 Revista de la Facultad de Ciencias Médicas de Córdoba; Vol. 82 Núm. 1 (2025); 127-139 Revista da Faculdade de Ciências Médicas de Córdoba; v. 82 n. 1 (2025); 127-139 1853-0605 0014-6722 10.31053/1853.0605.v82.n1 spa https://revistas.unc.edu.ar/index.php/med/article/view/44424/48670 https://revistas.unc.edu.ar/index.php/med/article/view/44424/48607 Derechos de autor 2025 Universidad Nacional de Córdoba https://creativecommons.org/licenses/by-nc/4.0 |